Cargando…

An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease

The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Meunier, Marine, Spillmann, Adrian, Rousseaux, Christel, Schwamborn, Klaus, Hanson, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461820/
https://www.ncbi.nlm.nih.gov/pubmed/37639428
http://dx.doi.org/10.1371/journal.pone.0283489
_version_ 1785097916546809856
author Meunier, Marine
Spillmann, Adrian
Rousseaux, Christel
Schwamborn, Klaus
Hanson, Melissa
author_facet Meunier, Marine
Spillmann, Adrian
Rousseaux, Christel
Schwamborn, Klaus
Hanson, Melissa
author_sort Meunier, Marine
collection PubMed
description The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients.
format Online
Article
Text
id pubmed-10461820
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-104618202023-08-29 An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease Meunier, Marine Spillmann, Adrian Rousseaux, Christel Schwamborn, Klaus Hanson, Melissa PLoS One Research Article The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients. Public Library of Science 2023-08-28 /pmc/articles/PMC10461820/ /pubmed/37639428 http://dx.doi.org/10.1371/journal.pone.0283489 Text en © 2023 Meunier et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Meunier, Marine
Spillmann, Adrian
Rousseaux, Christel
Schwamborn, Klaus
Hanson, Melissa
An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
title An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
title_full An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
title_fullStr An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
title_full_unstemmed An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
title_short An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
title_sort oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461820/
https://www.ncbi.nlm.nih.gov/pubmed/37639428
http://dx.doi.org/10.1371/journal.pone.0283489
work_keys_str_mv AT meuniermarine anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT spillmannadrian anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT rousseauxchristel anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT schwambornklaus anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT hansonmelissa anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT meuniermarine oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT spillmannadrian oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT rousseauxchristel oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT schwambornklaus oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease
AT hansonmelissa oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease